IRONWOOD PHARMACEUTICALS INC (IRWD) Stock Price & Overview
NASDAQ:IRWD • US46333X1081
The current stock price of IRWD is 3.5 USD. Today IRWD is down by -3.31%. In the past month the price decreased by -21.35%. In the past year, price increased by 133.33%.
IRWD Key Statistics
- Market Cap
- 570.71M
- P/E
- 15.22
- Fwd P/E
- 2.97
- EPS (TTM)
- 0.23
- Dividend Yield
- N/A
IRWD Stock Performance
IRWD Stock Chart
IRWD Technical Analysis
ChartMill assigns a technical rating of 6 / 10 to IRWD. When comparing the yearly performance of all stocks, IRWD is one of the better performing stocks in the market, outperforming 94.68% of all stocks.
IRWD Fundamental Analysis
ChartMill assigns a fundamental rating of 5 / 10 to IRWD. IRWD scores excellent on profitability, but there are some minor concerns on its financial health.
IRWD Earnings
On February 25, 2026 IRWD reported an EPS of -0.01 and a revenue of 47.71M. The company missed EPS expectations (-198.04% surprise) and missed revenue expectations (-8.17% surprise).
IRWD Forecast & Estimates
10 analysts have analysed IRWD and the average price target is 4.95 USD. This implies a price increase of 41.34% is expected in the next year compared to the current price of 3.5.
For the next year, analysts expect an EPS growth of 412.22% and a revenue growth 53.26% for IRWD
IRWD Groups
Sector & Classification
IRWD Financial Highlights
Over the last trailing twelve months IRWD reported a non-GAAP Earnings per Share(EPS) of 0.23. The EPS increased by 1050% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | 8.11% | ||
| ROA | 6.05% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
IRWD Ownership
IRWD Latest News, Press Relases and Analysis
IRWD Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.51 | 406.874B | ||
| AMGN | AMGEN INC | 16.19 | 199.203B | ||
| GILD | GILEAD SCIENCES INC | 16.28 | 178.678B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 23.56 | 116.013B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.25 | 80.332B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 42.98 | 42.526B | ||
| INSM | INSMED INC | N/A | 30.205B | ||
| NTRA | NATERA INC | N/A | 28.081B | ||
| BIIB | BIOGEN INC | 11.5 | 27.132B | ||
| UTHR | UNITED THERAPEUTICS CORP | 16.01 | 20.958B | ||
| MRNA | MODERNA INC | N/A | 20.742B | ||
| EXAS | EXACT SCIENCES CORP | 340.51 | 19.757B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.5B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About IRWD
Company Profile
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Company Info
IRONWOOD PHARMACEUTICALS INC
100 Summer Street, Suite 2300
Boston MASSACHUSETTS 02110 US
CEO: Mark Mallon
Employees: 100
Phone: 16176217722
IRONWOOD PHARMACEUTICALS INC / IRWD FAQ
What does IRWD do?
Ironwood Pharmaceuticals, Inc. is a healthcare company, which engages in the development and commercialization of Gastrointestinal (GI) products. The company is headquartered in Boston, Massachusetts and currently employs 100 full-time employees. The company went IPO on 2010-02-03. The company is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The firm is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.
Can you provide the latest stock price for IRONWOOD PHARMACEUTICALS INC?
The current stock price of IRWD is 3.5 USD. The price decreased by -3.31% in the last trading session.
What is the dividend status of IRONWOOD PHARMACEUTICALS INC?
IRWD does not pay a dividend.
How is the ChartMill rating for IRONWOOD PHARMACEUTICALS INC?
IRWD has a ChartMill Technical rating of 6 out of 10 and a ChartMill Fundamental rating of 5 out of 10.
What is the analyst forecast for IRWD stock?
10 analysts have analysed IRWD and the average price target is 4.95 USD. This implies a price increase of 41.34% is expected in the next year compared to the current price of 3.5.
How is the valuation of IRONWOOD PHARMACEUTICALS INC (IRWD) based on its PE ratio?
The PE ratio for IRONWOOD PHARMACEUTICALS INC (IRWD) is 15.22. This is based on the reported non-GAAP earnings per share of 0.23 and the current share price of 3.5 USD.
Can you provide the short interest for IRWD stock?
The outstanding short interest for IRONWOOD PHARMACEUTICALS INC (IRWD) is 7.03% of its float.